Press Releases

AMA applauds FDA for approving naloxone product to prevent overdoses

| 2 Min Read

“The American Medical Association (AMA) applauds the Food and Drug Administration (FDA) for approving the nasal spray version of naloxone, a life-saving medication that can reverse the effects of an opioid overdose by restoring breathing and preventing death. The FDA’s swift action will widely increase accessibility to this medication that will help prevent more opioid-related overdoses and save more lives.

“The AMA has long advocated in support of a multi-pronged approach to addressing prescription drug abuse and diversion, which includes increasing access to naloxone for patients who need it.

Full press statement available when you sign in

Sign in to the AMA website to get the full version of this press statement. 

AMA membership has its advantages

  • Be a part of the nation's largest physician organization
  • Play a role in shaping the future of health care
  • Enjoy exclusive perks and savings

Not a member? Become a member now.

 

FEATURED STORIES

Woman handing an insurance card to a doctor who is reviewing paperwork

AMA report: Health insurance giants tighten grip on U.S. markets

Dec 16, 2025
Patients in a waiting room at a doctor's office

What to expect from the 2026 Medicare Physician Fee Schedule

| 7 Min Read
Row of blocks with businesspeople with one being taken away

4 “Big, Beautiful Bill” changes that will reshape care in 2026

| 6 Min Read
Wood poles with question mark symbols

PAs push to enshrine “physician associate” term in law

| 6 Min Read